Studies have found that downregulating the CLK1 gene in glioma GL261 cells can inhibit mitochondrial function, reduce AMPK phosphorylation levels, activate the mTOR signaling pathway, promote the upregulation of HIF-1α in tumor cells, and enhance the sensitivity of GL261 cells to chemotherapy drugs. This evidence concerns the gene CLK1 and central nervous system cancer.